Bio-Holdings Ltd. is a subsidiary of Hadasit, Hadassah’s biotechnology transfer company. The grant is specifically for conducting research on the use of neural cells derived from human embryonic stem cells to treat Parkinson’s disease. “The Michael J. Fox Foundation is one of the most influential bodies in the fight against Parkinson’s,” said Dr. Charles Irving, Chief Operating Officer of Cell Cure. “We are delighted that the Foundation has recognized this project’s potential to have a major impact on millions of lives. The award will aid our scientific team in advancing this important research toward clinical trials in humans.” Founded in 2000, The Michael J. Fox Foundation for Parkinson’s Research is dedicated to ensuring the development of a cure for Parkinson’s disease within this decade through an aggressively funded research agenda. The Foundation has funded over $90 million in research to date, either directly or through partnerships.
Cell Cure is developing human embryonic stem cell-based therapies for various neural disorders (such as Parkinson’s, Multiple Sclerosis, ALS, and other neurodegenerative diseases). It is focused on the conversion of human embryonic stem cells into dopamine-producing neurons. These neurons will form the basis of new cell replacement therapies for Parkinson’s disease and will provide the dopamine that the damaged neurons in Parkinson’s patients can no longer produce.
Cell Cure is jointly owned by ES Cell International (ESI – a Singapore-based corporation) and Hadasit Bio-Holdings, which is publicly traded on the Tel Aviv Stock Exchange.